Stock Analiz

Cardiff Oncology, Inc. CRDF

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$0.73Market cap $56M
Open the interactive analysis →

Cardiff Oncology, Inc. (CRDF) is a healthcare company listed in the US with a market value of about $56M. In the twelve months to September 30, 2026 it had revenue of $559000 and net income of -$38M, a net margin of -6735.2%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 10% a year, a 5-year average ROIC of -52%.

About Cardiff Oncology

Cardiff Oncology is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $280178 in 2014 to $593000 in 2025, growth of about 7.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 53% over three years (dilution for shareholders). It spends 5958% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth2/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S101.1
P/B2.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-70.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-13.2%
Revenue growth (5 yrs, per year)10.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-8156.6%
ROIC (5-yr avg.)-51.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$559000$593000$683000$488000$386000$359000$365993$244632$378325$505404$381072
Net income-$38M-$46M-$45M-$41M-$39M-$28M-$19M-$16M-$16M-$25M-$39M
Free cash flow-$40M-$38M-$38M-$31M-$35M-$23M-$17M-$13M-$13M-$23M-$32M
EPS (diluted)$-0.55$-0.69$-0.95$-0.93$-0.89$-0.73$-1.08$-2.80$-8.26$-51.76$-98.64
Net margin-6735.2%-7732.0%-6651.7%-8492.0%-10026.9%-7880.5%-5275.2%-6709.7%-4351.1%-4928.1%-10287.8%
ROIC—-105.9%-57.6%-49.9%-28.9%-15.9%-11.7%-145.8%-133.6%-258.0%-87.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $6.28, 765% above the current price; targets range from $1.20 to $12.00; the consensus rating is “Buy”; expected EPS is $-0.56 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Cardiff Oncology pay a dividend?

Not currently.

Is Cardiff Oncology a good stock to buy?

We do not give buy or sell advice. Cardiff Oncology scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.